A drug used to treat Type 2 diabetes and obesity could also slow down the process of ageing, researchers believe.
Semaglutide, better known as Ozempic, "has far-reaching benefits beyond what we initially imagined," Prof Harlan Krumholz, from the Yale School of Medicine, said following the publication of several new studies.
They found that the drug could be used to treat a wide range of illnesses linked to heart failure, arthritis, Alzheimer's and even cancer.
The new data has been published in a number of medical journals, including the Journal of the American College of Cardiology (JACC), which Prof Krumholz edits.
Subscribe here: http://bit.ly/1rbfUog
For more news, analysis and features visit: www.bbc.com/news
#Ozempic #BBCNews
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in Patients With Overweight or Obesity) trial randomized 17,604 participants ≥45 years of age with a body mass index ≥27 kg/m2 with established CV disease but without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or placebo; the mean trial duration was 3.3 years. Adjudicated causes of all deaths, COVID-19 cases, and associated deaths were captured prospectively.
Of 833 deaths, 485 (58%) were CV deaths, and 348 (42%) were non-CV deaths. Participants assigned to semaglutide vs placebo had lower rates of all-cause death (HR: 0.81; 95% CI: 0.71-0.93), CV death (HR: 0.85; 95% CI: 0.71-1.01), and non-CV death (HR: 0.77; 95% CI: 0.62-0.95). The most common causes of CV death with semaglutide vs placebo were sudden cardiac death (98 vs 109; HR: 0.89; 95% CI: 0.68-1.17) and undetermined death (77 vs 90; HR: 0.85; 95% CI: 0.63-1.15). Infection was the most common cause of non-CV death and occurred at a lower rate in the semaglutide vs the placebo group (62 vs 87; HR: 0.71; 95% CI: 0.51-0.98). Semaglutide did not reduce incident COVID-19; however, among participants who developed COVID-19, fewer participants treated with semaglutide had COVID-19–related serious adverse events (232 vs 277; P = 0.04) or died of COVID-19 (43 vs 65; HR: 0.66; 95% CI: 0.44-0.96). High rates of infectious deaths occurred during the COVID-19 pandemic, with less infectious death in the semaglutide arm, and resulted in fewer participants in the placebo group being at risk for CV death.
High rates of infectious deaths occurred during the COVID-19 pandemic, with less infectious death in the semaglutide arm, and resulted in fewer participants in the placebo group being at risk for CV death.
“So many people died from covid that we had to account for the fact that people who already died from covid couldn’t die from cardiovascular disease”
Here is the actual article
https://www.sciencedirect.com/science/article/pii/S0735109724081567
“So many people died from covid that we had to account for the fact that people who already died from covid couldn’t die from cardiovascular disease”
Fucking bleak
Shame the people proclaiming covid is getting less deadly never account for all the people who have already died from covid